Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity

키워드

참고문헌 (82)

1. Olshansky SJ, "A potential decline in life expectancy in the United States in the 21st century", N Engl J Med, 352, pp.1138~1145 (2005)
2. Adams TD, "Long-term mortality after gastric bypass surgery", N Engl J Med, 357, pp.753~761 (2007)
3. Maggard MA, "Meta-analysis: surgical treatment of obesity", Ann Intern Med, 142, pp.547~559 (2005)
4. Marsk R, "Antiobesity surgery in Sweden from 1980 to 2005: a population-based study with a focus on mortality", Ann Surg, 248, pp.777~781 (2008)
5. Weiss EC, "Weight regain in U.S. adults who experienced substantial weight loss, 1999-2002", Am J Prev Med, 33, pp.34~40 (2007)
6. Hutton B, "Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials", Am J Clin Nutr, 80, pp.1461~1468 (2004)
7. Greenway FL, "Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial", Lancet, 376, pp.595~605 (2010)
8. Delzenne N, "Gastrointestinal targets of appetite regulation in humans", Obes Rev, 11, pp.234~250 (2010)
9. Farooqi IS, "Leptin regulates striatal regions and human eating behavior", Science, 317, pp.1355~ (2007)
10. Morris DL, "Recent advances in understanding leptin signaling and leptin resistance", Am J Physiol Endocrinol Metab, 297, pp.E1247~E1259 (2009)
11. Zheng H, "Eating for pleasure or calories", Curr Opin Pharmacol, 7, pp.607~612 (2007)
12. Olney JW, "Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate", Science, 164, pp.719~721 (1969)
13. Clark JT, "Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats", Endocrinology, 115, pp.427~429 (1984)
14. Schwartz MW, "Central nervous system control of food intake", Nature, 404, pp.661~671 (2000)
15. Rossi M, "A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo", Endocrinology, 139, pp.4428~4431 (1998)
16. Kristensen P, "Hypothalamic CART is a new anorectic peptide regulated by leptin", Nature, 393, pp.72~76 (1998)
17. Abbott CR, "Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei", Endocrinology, 142, pp.3457~3463 (2001)
18. Leibowitz SF, "Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat", Physiol Behav, 27, pp.1031~1040 (1981)
19. Bailey EF, "A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on “BDNF", TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat,” by Bariohay et al, 2008, pp.295, R1048~R1049
20. Ter Horst GJ, "Ascending projections from the solitary tract nucleus to the hypothalamus. A Phaseolus vulgaris lectin tracing study in the rat", Neuroscience, 31, pp.785~797 (1989)
21. Ter Horst GJ, "Descending pathways from hypothalamus to dorsal motor vagus and ambiguus nuclei in the rat", J Auton Nerv Syst, 11, pp.59~75 (1984)
22. Schwartz GJ, "The role of gastrointestinal vagal afferents in the control of food intake: current prospects", Nutrition, 16, pp.866~873 (2000)
23. Zheng H, "Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens", J Neurosci, 27, pp.11075~11082 (2007)
24. Petrovich GD, "Amygdalohypothalamic circuit allows learned cues to override satiety and promote eating", J Neurosci, 22, pp.8748~8753 (2002)
25. Kringelbach ML, "The human orbitofrontal cortex: linking reward to hedonic experience", Nat Rev Neurosci, 6, pp.691~702 (2005)
26. Verhagen JV, "The neurocognitive bases of human multimodal food perception: consciousness", Brain Res Rev, 53, pp.271~286 (2007)
27. Borg CM, "Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety", Br J Surg, 93, pp.210~215 (2006)
28. le Roux CW, "Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters", Ann Surg, 243, pp.108~114 (2006)
29. le Roux CW, "Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass", Ann Surg, 246, pp.780~785 (2007)
30. Adrian TE, "Human distribution and release of a putative new gut hormone, peptide YY", Gastroenterology, 89, pp.1070~1077 (1985)
31. peptide YY3-36 as selective Y1 and Y2 radioligands, "J Pharmacol Exp Ther", 1995, 673~680
32. Grandt D, "Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36", Regul Pept, 51, pp.151~159 (1994)
33. Degen L, "Effect of peptide YY3-36 on food intake in humans", Gastroenterology, 129, pp.1430~1436 (2005)
34. Lluis F, "Cellular localization, half-life, and secretion of peptide YY", Rev Esp Fisiol, 45, pp.377~384 (1989)
35. Essah PA, "Effect of macronutrient composition on postprandial peptide YY levels", J Clin Endocrinol Metab, 92, pp.4052~4055 (2007)
36. Helou N, "Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females", Ann Nutr Metab, 52, pp.188~195 (2008)
37. Batterham RL, "Gut hormone PYY(3-36) physiologically inhibits food intake", Nature, 418, pp.650~654 (2002)
38. Batterham RL, "Inhibition of food intake in obese subjects by peptide YY3-36", N Engl J Med, 349, pp.941~948 (2003)
39. Sloth B, "Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects", Am J Physiol Endocrinol Metab, 292, pp.E1062~E1068 (2007)
40. Gustafson EL, "Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system", Brain Res Mol Brain Res, 46, pp.223~235 (1997)
41. Blevins JE, "PYY(3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats", Peptides, 29, pp.112~119 (2008)
42. Dumont Y, "Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains", J Comp Neurol, 402, pp.372~384 (1998)
43. Koda S, "The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats", Endocrinology, 146, pp.2369~2375 (2005)
44. Batterham RL, "PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans", Nature, 450, pp.106~109 (2007)
45. Morley JE, "Peptide YY (PYY), a potent orexigenic agent", Brain Res, 341, pp.200~203 (1985)
46. Stanley BG, "Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion", Peptides, 6, pp.1205~1211 (1985)
47. Kanatani A, "Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice", Endocrinology, 141, pp.1011~1016 (2000)
48. Gantz I, "Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults", J Clin Endocrinol Metab, 92, pp.1754~1757 (2007)
49. Steinert RE, "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects", Am J Clin Nutr, 92, pp.810~817 (2010)
50. Ghatei MA, "Molecular forms of glucagon-like immunoreactivity in porcine intestine and pancreas", Endocrinology, 112, pp.917~923 (1983)
51. Orskov C, "Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans", Diabetes, 43, pp.535~539 (1994)
52. Smeets AJ, "Energy expenditure, satiety, and plasma ghrelin, glucagon-like peptide 1, and peptide tyrosine-tyrosine concentrations following a single high-protein lunch", J Nutr, 138, pp.698~702 (2008)
53. Edfalk S, "Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion", Diabetes, 57, pp.2280~2287 (2008)
54. Chu ZL, "A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release", Endocrinology, 149, pp.2038~2047 (2008)
55. Lauffer LM, "GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell", Diabetes, 58, pp.1058~1066 (2009)
56. Hirasawa A, "Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120", Nat Med, 11, pp.90~94 (2005)
57. Kieffer TJ, "Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV", Endocrinology, 136, pp.3585~3596 (1995)
58. Thorens B, "Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor", Diabetes, 42, pp.1678~1682 (1993)
59. Kreymann B, "Glucagonlike peptide-1 7-36: a physiological incretin in man", Lancet, 2, pp.1300~1304 (1987)
60. Gutniak M, "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus", N Engl J Med, 326, pp.1316~1322 (1992)
61. Willms B, "Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients", J Clin Endocrinol Metab, 81, pp.327~332 (1996)
62. Wei Y, "Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences", FEBS Lett, 358, pp.219~224 (1995)
63. Shughrue PJ, "Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus", Endocrinology, 137, pp.5159~5162 (1996)
64. Larsen PJ, "Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat", Endocrinology, 138, pp.4445~4455 (1997)
65. Turton MD, "A role for glucagon-like peptide-1 in the central regulation of feeding", Nature, 379, pp.69~72 (1996)
66. Verdich C, "A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans", J Clin Endocrinol Metab, 86, pp.4382~4389 (2001)
67. Näslund E, "Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects", Br J Nutr, 91, pp.439~446 (2004)
68. Baggio LL, "Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure", Gastroenterology, 127, pp.546~558 (2004)
69. Abbott CR, "The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagalbrainstem-hypothalamic pathway", Brain Res, 1044, pp.127~131 (2005)
70. Pannacciulli N, "Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans", Neuroimage, 35, pp.511~517 (2007)
71. Ratner RE, "Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus", Diabetes Obes Metab, 8, pp.419~428 (2006)
72. Riddle MC, "Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin", Diabetes Metab Res Rev, 22, pp.483~491 (2006)
73. Nauck M, "Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study", Diabetes Care, 32, pp.84~90 (2009)
74. Zinman B, "Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)", Diabetes Care, 32, pp.1224~1230 (2009)
75. Garber A, "Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial", Lancet, 373, pp.473~481 (2009)
76. Marre M, "Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)", Diabet Med, 26, pp.268~278 (2009)
77. Knudsen LB, "Small-molecule agonists for the glucagon-like peptide 1 receptor", Proc Natl Acad Sci U S A, 104, pp.937~942 (2007)
78. Chen D, "A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db", db mice, 2007, pp.104, 943~948
79. Green BD, "Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes", Diab Vasc Dis Res, 3, pp.159~165 (2006)
80. Lauffer L, "GPR119: “double-dipping” for better glycemic control", Endocrinology, 149, pp.2035~2037 (2008)
81. Astrup A, "Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebocontrolled study", Lancet, 374, pp.1606~1616 (2009)
82. Neary NM, "Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively", Endocrinology, 146, pp.5120~5127 (2005)

관련 논문AI추천